| Expression pattern: |
DN |
| Associated gene: |
P27, P21 |
| Associated microRNA: |
miR-222-3p, miR-146a-5p |
| Biological function: |
Inhibits urothelial carcinoma cell proliferation, induces G1 cell cycle arrest and apoptosis, and increases cisplatin sensitivity/attenuates cisplatin chemoresistance. |
| Molecular mechanism: |
circFAM114A2 acts as a miRNA sponge for miR-222-3p and miR-146a-5p, thereby relieving repression of P27 and P21 (respectively) and promoting G1 arrest and cisplatin chemosensitivity. |
| Biological pathway or process: |
cell cycle (inhibits); proliferation (inhibits); apoptosis (promotes); chemoresistance (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; FISH / smFISH; Bioinformatics Analysis; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Colony Formation Assay; In Vivo Animal Model; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation; Cohort Study; Survival Analysis |
| Clinical significance: |
Higher circFAM114A2 expression was associated with lower histological grade and better overall survival in urothelial carcinoma patients, suggesting prognostic biomarker potential. |
| Description: |
circFAM114A2 is downregulated in urothelial carcinoma and functions as a tumor-suppressive circRNA. It sponges miR-222-3p and miR-146a-5p to upregulate P27 and P21, promoting G1 arrest and apoptosis and enhancing cisplatin sensitivity in vitro and in xenograft models; higher expression predicts better survival. |
| Confidence score: |
0.8823 |